contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


new-article-using-attanas-technology-from-national-university-of-singapore-immunity-differences-in-vaccinated-individuals-according-to-age-gender-lifestyle-and-other-diseases

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Attana conducts research and development of pharmaceuticals. The company specialises in vitro characterization of molecular interactions, which is used for analysis in the development of new pharmaceuticals. The company's patented solutions are mainly used in the study of different binding properties and macrostructures in cells, proteins, viruses, and bacteria. Operations are found mainly within the Nordic countries and Europe. The company was established in 2002 is based in Stockholm.

Attana

 The article presented quantification of serological immunity against SARS-CoV-2 variants. Differences in immunity are seen against the different variants and depending on age, sex, ethnicity...

<div class="abstract">&nbsp;The article presented quantification of serological immunity against SARS-CoV-2 variants. Differences in immunity are seen against the different variants and depending on age, sex, ethnicity and lifestyle, but e.g. high blood pressure or BMI did not show significant differences in the serological immunity of individuals vaccinated against the Wuhan variant. The study also showed poorer immunity to Omicron than to Wuhan, but after the third vaccine dose, an increased cross-reactivity between the different covid variants was shown.</div>To strengthen the serological profiling of the donor plasma samples, Attana QCM was used to study the interaction kinetics between the ACE2 receptor and Wuhan and other variants (Alpha, Beta, Gamma, Delta, Epsilon and Kappa and Omicron). The affinity varied by more than an order of magnitude and clear differences in the interaction kinetics were observed. Overall, neutralization in Wuhan was among the strongest among the variants tested, which was expected as the vaccine was developed against the Wuhan variant. Significantly inferior neutralizing efficacy was observed against the Beta and Gamma strains compared to Wuhan at all time points tested up to 6 months post-vaccination. The average neutralization against all variants was just over 40%. The results also showed the following significant differences:<ul><li>Women showed better protection against all variants than men.</li><li>60 years and older showed a significantly lower protection compared to those under 40 years.</li><li>Vaccinees of Indian ethnicity showed a small, but significantly stronger, peak response to the Gamma variant compared to those of Chinese ethnicity. In addition, differences were detected against the alpha and beta variants between these two cohorts. Although this needs to be validated in larger cohorts, this raises the possibility that significant ethnic differences in vaccine response may exist.</li><li>Former, but not active, smokers showed higher protection compared to non-smokers.</li><li>BMI and comorbidities such as high blood pressure and high cholesterol had no effect on the observed neutralizing titers.</li></ul>

New article using Attana's technology from National University of Singapore: Immunity differences in vaccinated individuals according to age, gender, lifestyle and other diseases